[Risk of medicines in pregnancy: a problem of knowledge transfer with ethical implications].

Drug use in pregnancy is essential and beneficial, but it is needed to check their safety. Available scientific evidence is poor and difficult to interpret. Risk classifications (FDA, ADEC) have shown to be too simple and categorical; they lead to inaccurate perceptions of risk and unfortunate decisions, such as interrumption of medication, or abortion. This has become clear with antidepressants or the antiretroviral efavirenz. Although abortion is not justified, misinformation contributes even more to the problem. Information tends to obviate that not every risk in pregnancy is teratogenic, that the existence of risk does not imply high probability, and that the nature and probability of the risk vary according to the stage.

[1]  Marie Catherine Lee,et al.  Treatment of the Pregnant Patient with Breast Cancer , 2017, Southern medical journal.

[2]  F. Amant,et al.  Cancer in pregnancy: safety and efficacy of systemic therapies , 2017, Current opinion in oncology.

[3]  T. Cheetham,et al.  Identifying birth defects in automated data sources in the Vaccine Safety Datalink , 2017, Pharmacoepidemiology and drug safety.

[4]  J. Ash,et al.  Evaluation of risk communication in a mammography patient decision aid. , 2016, Patient education and counseling.

[5]  V. Rousson,et al.  Pregnancy outcome following maternal exposure to pregabalin may call for concern , 2016, Neurology.

[6]  J. Schjøtt,et al.  Physicians' Perception of Teratogenic Risk and Confidence in Prescribing Drugs in Pregnancy-Influence of Norwegian Drug Information Centers. , 2016, Clinical therapeutics.

[7]  Elyse Watkins,et al.  Understanding the new pregnancy and lactation drug labeling. , 2016, JAAPA : official journal of the American Academy of Physician Assistants.

[8]  M. Costantine,et al.  Epidemiology of medications use in pregnancy. , 2015, Seminars in perinatology.

[9]  S. Caritis,et al.  Pharmacokinetics of drugs in pregnancy. , 2015, Seminars in perinatology.

[10]  H. C. Fantasia,et al.  Changes to Pregnancy and Lactation Risk Labeling for Prescription Drugs. , 2015, Nursing for women's health.

[11]  T. Egberts,et al.  Antidepressant use in pregnancy: knowledge transfer and translation of research findings. , 2015, Journal of evaluation in clinical practice.

[12]  S. Hernández-Díaz,et al.  Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk , 2013, Pharmacoepidemiology and drug safety.

[13]  A. Einarson.  Antidepressant use during pregnancy: navigating the sea of information. , 2013, Canadian family physician Medecin de famille canadien.

[14]  C. Guille,et al.  Relapse of major depression in women who continue or discontinue antidepressant medication during pregnancy. , 2013, The American journal of psychiatry.

[15]  A. Einarson,et al.  Knowledge transfer and translation: examining how teratogen information is disseminated. , 2011, Birth defects research. Part A, Clinical and molecular teratology.

[16]  M. Adam,et al.  Evolving knowledge of the teratogenicity of medications in human pregnancy , 2011, American journal of medical genetics. Part C, Seminars in medical genetics.

[17]  G. Diamond,et al.  Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome , 2011, Journal of Perinatology.

[18]  G. Koren,et al.  International practices in the provision of teratology information: a survey of international teratogen information programmes and comparisons with the North American model. , 2010, Journal of evaluation in clinical practice.

[19]  L. Puig,et al.  Treatment of Psoriasis with Anti-TNF Drugs during Pregnancy: Case Report and Review of the Literature , 2009, Dermatology.

[20]  S. Rasmussen,et al.  Varicella vaccine exposure during pregnancy: data from 10 Years of the pregnancy registry. , 2008, The Journal of infectious diseases.

[21]  B. Vandermeer,et al.  Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis , 2006, BMJ : British Medical Journal.

[22]  M Gallego Úbeda,et al.  [An update in drug use during pregnancy: risk classification]. , 2014, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

[23]  I. Petersen,et al.  Selective serotonin reuptake inhibitors and risk for major congenital anomalies. , 2012, Obstetrics and gynecology.